[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06626022":3,"trial-entities:NCT06626022":189,"trial-summary:NCT06626022":193},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":15,"conditions":17,"keywords":19,"study_type":20,"primary_purpose":21,"phases":22,"enrollment_info":24,"interventions":27,"primary_outcomes":38,"secondary_outcomes":43,"sex":44,"minimum_age":45,"maximum_age":46,"healthy_volunteers":47,"eligibility_criteria":48,"std_ages":52,"locations":55,"central_contacts":174,"overall_officials":180,"references":183,"see_also_links":188},"NCT06626022","HREBA.CC-24-0325","Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging.","A Phase 3, Multicenter, International, Non-inferiority, Randomized Clinical Trial Comparing Screening for Prostate Cancer Using High Resolution Micro-ultrasound Versus Multiparametric Magnetic Resonance Imaging (MUSIC-Screen)","RECRUITING","2029-11-30","2026-06","2026-06-04","2025-05-08","University of Alberta","OTHER",null,"The purpose of this study is to compare whether the FDA and Health Canada approved microUS is as effective as the currently used option (MRI) for imaging the prostate gland. Participants will be randomized into two groups to compare the imaging results of the current standard of care MRI and the new microUS. The study is looking to identify the most effective imaging modality to help guide whether you progress to have a prostate biopsy.",[18],"Prostate Cancer Screening",[],"INTERVENTIONAL","SCREENING",[23],"PHASE3",{"count":25,"type":26},1284,"ESTIMATED",[28,33],{"type":29,"name":30,"description":31,"armGroupLabels":32},"DEVICE","MRI","Standard prostate mpMRI.",[30],{"type":29,"name":34,"description":35,"armGroupLabels":36},"ExactVu","microUltrasound",[37],"microUltransound",[39],{"measure":40,"description":41,"timeFrame":42},"Detection of Clinically significant prostate cancer.","The primary objective of this trial is to determine if a screening pathway using microUS is non-inferior to a pathway using MRI for the detection of clinically significant prostate cancer, defined as Gleason Grade Group 2 or more.","Once enrolled, men will be followed for 1 year after the imaging test.",[],"MALE","50 Years","70 Years",true,{"inclusion":49,"exclusion":50,"raw_text":51},[],[],"Inclusion Criteria:\n\n1. Male sex;\n2. Age 50-70;\n3. PSA 3-20 and\u002For abnormal DRE;\n4. Biopsy naïve.\n\nExclusion Criteria:\n\n1. Prior personal history of prostate cancer;\n2. Prior prostate imaging using microUS or MRI;\n3. Contraindication to microUS or MRI;\n4. Testosterone replacement therapy within last 12 months; or\n5. Androgen deprivation therapy within last 12 months.",[53,54],"ADULT","OLDER_ADULT",[56,75,90,99,112,128,138,152,162],{"facility":57,"status":58,"city":59,"state":60,"zip":61,"country":62,"contacts":63,"geoPoint":72},"University of California, Los Angeles (UCLA)","NOT_YET_RECRUITING","Los Angeles","California","90095","United States",[64,69],{"name":65,"role":66,"phone":67,"email":68},"Ankush Sachdeva","CONTACT","310-794-3452","ASachdeva@mednet.ucla.edu",{"name":70,"role":71},"Wayne Brisbane, MD","PRINCIPAL_INVESTIGATOR",{"lat":73,"lon":74},34.05223,-118.24368,{"facility":76,"status":58,"city":77,"state":78,"zip":79,"country":62,"contacts":80,"geoPoint":87},"UT Southwestern Medical Center","Dallas","Texas","75390",[81,85],{"name":82,"role":66,"phone":83,"email":84},"Sonobia Garrett","214-645-8787","Sonobia.Garrett@UTSouthwestern.edu",{"name":86,"role":71},"Xiaosong Meng, MD, PhD",{"lat":88,"lon":89},32.78306,-96.80667,{"facility":13,"status":91,"city":92,"state":93,"zip":94,"country":95,"geoPoint":96},"ACTIVE_NOT_RECRUITING","Edmonton","Alberta","T6G 1Z1","Canada",{"lat":97,"lon":98},53.55014,-113.46871,{"facility":100,"status":58,"city":101,"state":102,"zip":103,"country":95,"contacts":104,"geoPoint":109},"University of British Columbia","Vancouver","British Columbia","V5Z 1M9",[105,108],{"name":106,"role":66,"email":107},"Miles Mannas, MD","mmannas@mail.ubc.ca",{"name":106,"role":71},{"lat":110,"lon":111},49.24966,-123.11934,{"facility":113,"status":8,"city":114,"state":115,"zip":116,"country":95,"contacts":117,"geoPoint":125},"Sunnybrook Health Sciences Centre","Toronto","Ontario","M4N 3M5",[118,123],{"name":119,"role":66,"phone":120,"phoneExt":121,"email":122},"Shania Nigli","416-480-6100","2890","shania.nigli@sunnybrook.ca",{"name":124,"role":71},"Laurence Klotz, MD",{"lat":126,"lon":127},43.70643,-79.39864,{"facility":129,"status":58,"city":130,"state":131,"zip":132,"country":95,"contacts":133},"CIUSSS du Nord-de-l'Île-de-Montréal","Montréal","Quebec","H4J 1C5",[134,137],{"name":135,"role":66,"email":136},"Hugo Lavigueur-Blouin, MD","hugo.lavigueur-blouin.med@ssss.gouv.qc.ca",{"name":135,"role":71},{"facility":139,"status":8,"city":140,"country":141,"contacts":142,"geoPoint":149},"CH de Martigues","Martigues","France",[143,147],{"name":144,"role":66,"phone":145,"email":146},"Gwladys M-Bou, MD","04 42 43 24 69","Gwladys.MBOUNGOU@ch-martigues.fr",{"name":148,"role":71},"Harry Toledano, MD",{"lat":150,"lon":151},43.40735,5.05526,{"facility":153,"status":8,"city":154,"country":155,"contacts":156,"geoPoint":159},"Vestfold Hospital Trust","Tønsberg","Norway",[157],{"name":158,"role":71},"Sven Loffeler, PhD, MD",{"lat":160,"lon":161},59.26754,10.40762,{"facility":163,"status":8,"city":164,"country":165,"contacts":166,"geoPoint":171},"Urologia Clinica Bilbao","Bilbao","Spain",[167,170],{"name":168,"role":66,"email":169},"Felipe Urdaneta, MD","luisurdaneta03@yahoo.com",{"name":168,"role":71},{"lat":172,"lon":173},43.26271,-2.92528,[175],{"name":176,"role":66,"phone":177,"phoneExt":178,"email":179},"Stacey Broomfield, PhD","+1-780-407-5800","321","sbroomfi@ualberta.ca",[181],{"name":182,"affiliation":13,"role":71},"Adam Kinnaird, MD, PhD",[184],{"pmid":185,"type":186,"citation":187},"42476253","DERIVED","Guer M, Beksac AT, Brisbane W, Cash H, Ghai S, Ghosh S, Heinrichs A, Klotz L, Lavigueur-Blouin H, Loffeler S, Lughezzani G, Mannas M, Meng X, Morgan TN, Nahar B, Rodrigues T, Struck JP, Tiwari R, Toledano H, Urdaneta F, Kinnaird A. Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis. Contemp Clin Trials. 2026 Sep;168:108410. doi: 10.1016\u002Fj.cct.2026.108410. Epub 2026 Jul 20.",[],{"nct_id":4,"conditions":190,"biomarkers":192},[191],"Prostate Carcinoma",[],{"nct_id":4,"found":47,"summary":194,"prompt_version":204},{"design":195,"status":196,"heading":197,"summary":198,"follow_up":199,"word_count":200,"commitments":201,"compensation":202,"drugs_mentioned":203},"This interventional study plans to enroll 1284 men. Participants will be randomly assigned to one of two groups to compare imaging results.","completed","Comparing Micro-ultrasound and MRI for Prostate Cancer Screening","This study is comparing two imaging methods, microUltrasound (ExactVu) and standard prostate mpMRI, to see which is better at finding important prostate cancers. You might be able to join if you are a man between 50 and 70 years old, have a PSA (Prostate Specific Antigen, a blood test for prostate health) between 3-20, and\u002For an abnormal DRE (Digital Rectal Exam). You also shouldn't have had a prostate biopsy before. The study aims to find the most effective way to image the prostate to help decide if a biopsy is needed. Participants will be randomly assigned to receive either ExactVu or mpMRI.","After your imaging test, you will be followed for one year to see if clinically significant prostate cancer is detected.",102,"Not specified in the trial record.","Not stated in the trial record.",[30,34],"v2"]